For the MYC- DLBCL patients, one patient out of 30 patients (3.3%) showed increased uptake at lesional level (MYC + : 4 out of 23; p = 0.085), and no patients showed increased MTV at I-PET compared to baseline (MYC + : 2 out of 23; p = 0.103). The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.